Following its Phase 1 investigation, the CMA has found that Theramex s proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
LONDON, October 10, 2023 Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals.
- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside
Theramex, a leading global pharmaceutical company specialising in women's health, has entered into a licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel
We have partnered with amazing organisations to celebrate this special day Our campaigns allow us to work harder than ever to improve women's lives Internal communication and campaigns